118 related articles for article (PubMed ID: 38760098)
1. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; She D; Rees W; Smith M; Cimbora D; Katz E; Bennett JL;
Lancet Neurol; 2024 Jun; 23(6):588-602. PubMed ID: 38760098
[TBL] [Abstract][Full Text] [Related]
2. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Cree BAC; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; Lublin FD; Drappa J; Barron G; Madani S; Ratchford JN; She D; Cimbora D; Katz E;
Lancet; 2019 Oct; 394(10206):1352-1363. PubMed ID: 31495497
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study.
Fujihara K; Kim HJ; Saida T; Misu T; Nagano Y; Totsuka N; Iizuka M; Kido S; Terata R; Okumura K; Hirota S; Cree BAC
Mult Scler Relat Disord; 2023 Nov; 79():104938. PubMed ID: 37769428
[TBL] [Abstract][Full Text] [Related]
4. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
Marignier R; Pittock SJ; Paul F; Kim HJ; Bennett JL; Weinshenker BG; Wingerchuk DM; Green AJ; Fujihara K; Cutter G; Aktas O; Hartung HP; Drappa J; Ratchford JN; She D; Smith M; Rees W; Cimbora D; Katz E; Cree BAC;
Mult Scler Relat Disord; 2022 Jan; 57():103356. PubMed ID: 35158465
[TBL] [Abstract][Full Text] [Related]
5. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study.
Flanagan EP; Levy M; Katz E; Cimbora D; Drappa J; Mealy MA; She D; Cree BAC
Mult Scler Relat Disord; 2022 Jan; 57():103352. PubMed ID: 35158461
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial.
Rensel M; Zabeti A; Mealy MA; Cimbora D; She D; Drappa J; Katz E
Mult Scler; 2022 May; 28(6):925-932. PubMed ID: 34595983
[TBL] [Abstract][Full Text] [Related]
7. Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.
Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk D; Fujihara K; Paul F; Cutter GR; Green AJ; Aktas O; Hartung HP; Lublin FD; Williams IM; Drappa J; She D; Cimbora D; Rees W; Smith M; Ratchford JN; Katz E; Cree BAC;
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33771837
[TBL] [Abstract][Full Text] [Related]
8. Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.
Bennett JL; Aktas O; Rees WA; Smith MA; Gunsior M; Yan L; She D; Cimbora D; Pittock SJ; Weinshenker BG; Paul F; Marignier R; Wingerchuk D; Cutter G; Green A; Hartung HP; Kim HJ; Fujihara K; Levy M; Katz E; Cree BAC;
EBioMedicine; 2022 Dec; 86():104321. PubMed ID: 36370634
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Traboulsee A; Greenberg BM; Bennett JL; Szczechowski L; Fox E; Shkrobot S; Yamamura T; Terada Y; Kawata Y; Wright P; Gianella-Borradori A; Garren H; Weinshenker BG
Lancet Neurol; 2020 May; 19(5):402-412. PubMed ID: 32333898
[TBL] [Abstract][Full Text] [Related]
10. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Nie T; Blair HA
CNS Drugs; 2022 Oct; 36(10):1133-1141. PubMed ID: 36070074
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
Cree BA; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk D; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; Williams IM; Drappa J; She D; Cimbora D; Rees W; Ratchford JN; Katz E
Mult Scler; 2021 Nov; 27(13):2052-2061. PubMed ID: 33538237
[TBL] [Abstract][Full Text] [Related]
12. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
[TBL] [Abstract][Full Text] [Related]
13. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
Aktas O; Hartung HP; Smith MA; Rees WA; Fujihara K; Paul F; Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Cutter G; She D; Gunsior M; Cimbora D; Katz E; Cree BA;
J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):757-768. PubMed ID: 37221052
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
Zhang C; Zhang M; Qiu W; Ma H; Zhang X; Zhu Z; Yang CS; Jia D; Zhang TX; Yuan M; Feng Y; Yang L; Lu W; Yu C; Bennett JL; Shi FD;
Lancet Neurol; 2020 May; 19(5):391-401. PubMed ID: 32333897
[TBL] [Abstract][Full Text] [Related]
15. Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder.
Siebert N; Duchow A; Paul F; Infante-Duarte C; Bellmann-Strobl J
Drugs Today (Barc); 2021 May; 57(5):321-336. PubMed ID: 34061127
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
[TBL] [Abstract][Full Text] [Related]
17. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
Pittock SJ; Berthele A; Fujihara K; Kim HJ; Levy M; Palace J; Nakashima I; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Fujita KP; Armstrong R; Wingerchuk DM
N Engl J Med; 2019 Aug; 381(7):614-625. PubMed ID: 31050279
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
[TBL] [Abstract][Full Text] [Related]
19. Inebilizumab for treatment of neuromyelitis optica spectrum disorder.
J Tullman M; Zabeti A; Vuocolo S; Dinh Q
Neurodegener Dis Manag; 2021 Oct; 11(5):341-352. PubMed ID: 34486379
[TBL] [Abstract][Full Text] [Related]
20. Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension.
Kim HJ; Nakashima I; Viswanathan S; Wang KC; Shang S; Miller L; Yountz M; Wingerchuk DM; Pittock SJ; Levy M; Berthele A; Totolyan N; Palace J; Barnett MH; Fujihara K;
Mult Scler Relat Disord; 2021 May; 50():102849. PubMed ID: 33676197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
